Clinical Research Center for Allergy and Rheumatology Reports Findings in Atopic Dermatitis (Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A...).

A recent study conducted in Sagamihara, Japan, investigated the efficacy and safety of dupilumab in Japanese pediatric patients with moderate-to-severe atopic dermatitis. The study found that dupilumab showed consistent efficacy and was well tolerated in patients aged 6 months to <18 years who had previously not responded well to existing therapies. The primary endpoint of the study was the proportion of patients with a 75% improvement in Eczema Area and Severity Index (EASI) score, and at week 16, more patients achieved this improvement with dupilumab compared to placebo. However, there was no significant difference in the proportion of patients achieving investigator global assessment (IGA) scores of 0/1 between the two groups. Overall, the study suggests that dupilumab may be a promising treatment option for Japanese pediatric patients with moderate-to-severe atopic dermatitis. [Extracted from the article]